Aeolus Pharmaceuticals Announces NIH Counteract Grant Award to Develop AEOL 10150 as a Treatment Against Nerve Agent Exposure
October 24, 2011 07:01 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Oct 24, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant funding from the U.S. Department of...
Aeolus Pharmaceuticals Announces $12.7 Million NIH Counteract Grant Award to Continue Development of AEOL 10150 as a Treatment Against Chlorine and Sulfur Mustard Gas Exposure
October 10, 2011 11:55 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Oct 10, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company that is leveraging up to $140M of government funding in...
Roth Capital Initiates Equity Research Analyst Coverage on Aeolus
October 05, 2011 11:28 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Oct 5, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company that is leveraging up to $140M of government funding in...
Aeolus Pharmaceuticals Files Request for Orphan Drug Designation of AEOL 10150 for Mitigation, and/or Treatment of Delayed Effects of Acute Radiation Exposure of the Lung
September 23, 2011 13:22 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Sep 23, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company that is leveraging up to $140M of government funding in...
Aeolus to Present at Stifel Nicolaus' Annual Healthcare Conference
September 06, 2011 17:41 ET
|
Aeolus
MISSION VIEJO, CA--(Marketwire - Sep 6, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company that is leveraging up to $140M of government funding in...
Aeolus Pharmaceuticals' Announces Presentation of AEOL10150 Data at the 14th International Congress of Radiation Research
September 01, 2011 11:16 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Sep 1, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company that is leveraging up to $140M of government funding in...
Ladenburg Thalmann Initiates Equity Research Analyst Coverage on Aeolus
August 29, 2011 14:33 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Aug 29, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS) today announced that Ladenburg Thalmann & Co. Inc. initiated equity research...
Aeolus Pharmaceuticals Announces Third Quarter Fiscal Year 2011 Results
August 15, 2011 16:56 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Aug 15, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) announced today financial results for the three months ended June 30, 2011. The Company reported net...
Noble Financial Initiates Equity Research Analyst Coverage on Aeolus
May 26, 2011 19:32 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - May 26, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced that Noble Financial Group initiated equity research coverage on the Company with a "Buy"...